[Experimental approaches to treatment of prostatic adenoma with the luliberin analog surfagon].
Therapeutic efficacy of surfagon, an analog of LH-RH which was injected subcutaneously at a daily dose of 100 micrograms/kg for 30 days, was investigated in ACI male rats with induced prostatic adenoma. This drug was shown to be effective proceeding from a morphological study and measurement of the prostate. Measurement of blood testosterone levels by radioimmunoassay showed a decrease in this level in rats, treated with surfagon, i. e. a therapeutic effect of the drug in prostatic adenoma was accompanied by a decrease in the level of androgens.
Smirnova
I O
IO
Balueva
I M
IM
Kiselev
V I
VI
Pavlova
O M
OM
Titov
M I
MI
Burenin
I S
IS
D000818:Animals; D007987:Gonadotropin-Releasing Hormone / Q000031:analogs & derivatives* / Q000627:therapeutic use; D006728:Hormones / Q000627:therapeutic use*; D008297:Male; D011470:Prostatic Hyperplasia / Q000097:blood / Q000188:drug therapy* / Q000473:pathology; D051381:Rats; D011912:Rats, Inbred ACI; D013739:Testosterone / Q000097:blood
D006728:Hormones; D007987:Gonadotropin-Releasing Hormone; D013739:Testosterone; C010661:surfagon
Eksperimental'nye podkhody k lecheniiu adenomy predstatel'noĭ zhelezy analogom liuliberina surfagonom.